4 results match your criteria: "Oregon Health and Science University (OHSU) Knight Cancer Institute[Affiliation]"
Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis.
Mol Oncol
August 2020
Department of Translational Molecular Medicine, John Wayne Cancer Institute (JWCI), Santa Monica, CA, USA.
Melanoma metastasis to the brain is one of the most frequent extracranial brain tumors. Cell surface gangliosides are elevated in melanoma metastasis; however, the metabolic regulatory mechanisms that govern these specific changes are poorly understood in melanoma particularly brain metastases (MBM) development. We found ganglioside GD3 levels significantly upregulated in MBM compared to lymph node metastasis (LNM) but not for other melanoma gangliosides.
View Article and Find Full Text PDFPatient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.
Blood Adv
February 2020
Peter MacCallum Cancer Centre, St Vincent's Hospital and University of Melbourne, Melbourne, VIC, Australia.
The JULIET phase 2 trial evaluated a single infusion of tisagenlecleucel in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The objective of the current analysis was to evaluate patient-reported health-related quality of life (HRQoL) with a median follow-up of 19.3 months among patients infused with a single dose of tisagenlecleucel.
View Article and Find Full Text PDFConcordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
J Natl Cancer Inst
December 2017
Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada; Institute of Biosciences and Medical Technology, University of Tampere, Tampere, Finland; Department of Medicine and Department of Radiation Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA; Oregon Health and Science University (OHSU) Knight Cancer Institute, Portland, OR; Department of Urology, University of California, Davis, School of Medicine, Sacremento, CA; Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada.
Background: Real-time knowledge of the somatic genome can influence management of patients with metastatic castration-resistant prostate cancer (mCRPC). While routine metastatic tissue biopsy is challenging in mCRPC, plasma circulating tumor DNA (ctDNA) has emerged as a minimally invasive tool to sample the tumor genome. However, no systematic comparisons of matched "liquid" and "solid" biopsies have been performed that would enable ctDNA profiling to replace the need for direct tissue sampling.
View Article and Find Full Text PDFCharacteristics of chronic GVHD after cord blood transplantation.
Bone Marrow Transplant
October 2013
1] Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA, USA [2] Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA [3] Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University (OHSU) Knight Cancer Institute, Portland, OR, USA.
Most reports of chronic GVHD after cord blood transplantation (CBT) have utilized traditional diagnostic criteria. We used traditional criteria and National Institutes of Health (NIH) criteria prospectively to evaluate chronic GVHD in a cohort of 87 adult and pediatric recipients of single or double unrelated CBT for treatment of hematologic malignancies. Fifty-four patients developed traditionally defined chronic GVHD, for an estimated 2-year probability of 64%.
View Article and Find Full Text PDF